About this document "Gmail thread": summarize

Summary of Gmail Thread: Marlo's Case Discussion

This email thread documents a collaborative "molecular hackathon" focused on developing a treatment strategy for Marlo "Mo" Kwong, a 2-year-old boy with an ultra-rare, aggressive sarcoma.

Key Medical Facts:

Diagnosis Evolution:

• Born with a low-grade spindle cell tumor (December 2023)
• Transformed to high-grade undifferentiated spindle cell sarcoma (October 2025)
• Primary driver: EGFR Internal Tandem Duplication (ITD) - a rare mutation
• Tumor location: Right brachial plexus, supraclavicular region, chest, mediastinum, T2-T3 spinal cord
• Currently: Regional disease (no lung metastases after 26 months)

Current Treatment:

• Receiving chemotherapy + radiation + erlotinib (1st generation EGFR inhibitor)
• Showing partial response to treatment

Main Discussion Points:

1. Treatment Strategy Debate:

• Should they switch from erlotinib to afatinib (2nd generation EGFR inhibitor)?
  • Real-world evidence: Another 2-year-old in Spain with same EGFR-ITD responded well to afatinib
• Timing of advanced therapies: CAR-T cell therapy (B7-H3 or HER2-targeted), antibody-drug conjugates, immunotherapy

2. Diagnostic Priorities:

• Need for additional testing: HER2 and B7-H3 immunohistochemistry (IHC) to determine CAR-T eligibility
• Pathology review emphasized - Mayo Clinic pathologist stated uncertainty about exact diagnosis
• Complex karyotype discovered in transformed tumor (PTEN loss, RB1 loss, MDM2/KRAS gain)

3. Key Contributors' Perspectives:

Allen Morris (Pathologist):

• Emphasized need for precise diagnosis before treatment planning
• Suggested blinded pathology reviews from multiple academic centers
• Raised question: Is this truly metastatic disease or regional/contiguous tumor?
• Advocated for local-regional treatment approach given lack of distant metastases
• Mentioned experimental integrin-targeted therapy as potential option

Chris Apfel (SageMedic):

• Praised AI analysis but noted limitations (focused on NCCN guidelines, clinical trials)
• Recommended functional drug testing (organoids, ex vivo testing)
• Prioritized: 1) CeGAT peptide vaccines, 2) SAGE functional testing, 3) CAR-T trials
• Noted CAR-T has better results in blood cancers than solid tumors

Ian Maurer (Software Developer):

• Generated comprehensive AI-powered analysis using BioMCP tools
• Second analysis incorporated complete [ID removed]
• Identified HER2 CAR-T trial at Baylor accepting "undifferentiated sarcoma"
• Recommended afatinib switch based on Spanish pediatric case

Critical Next Steps Identified:

1. Immediate Testing: HER2 and B7-H3 IHC to determine CAR-T eligibility
2. Treatment Decision: Consider switching to afatinib
3. Trial Pre-screening: Contact St. Jude and Baylor for CAR-T trials
4. Cardiac Assessment: Echo to assess eligibility for CAR-T
5. Pathology Review: Additional expert reviews for diagnostic certainty

Three Core Questions for Hackathon:

1. Optimal treatment sequence toward cure (cytoreduction → consolidation → maintenance)
2. Data/model requirements to guide decisions (additional genomic testing, functional models)
3. Access strategy (clinical trials vs. compassionate use vs. single-patient INDs)

Important Context:

This represents a "unicorn case" - extremely rare, requiring diagnosis by exclusion of 70+ molecularly-defined sarcoma entities. The collaborative approach involves pathologists, oncologists, bioinformaticians, and AI tools to develop a rational treatment path for a child with no established standard of care.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.